These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1061 related articles for article (PubMed ID: 2942646)

  • 1. Initial clinical studies with copovithane.
    Hortobagyi GN; Hersh EM; Papadopoulos NE; Frye D; Rios A; Reuben JM; Plager C; Rosenblum M; Quesada J
    J Biol Response Mod; 1986 Aug; 5(4):319-29. PubMed ID: 2942646
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A randomized study of two schedules of copovithane in patients with advanced colorectal carcinoma.
    Ajani JA; Hortobagyi GN; Frye D; Levin B; Boman BM; Faintuch JS
    Am J Clin Oncol; 1987 Apr; 10(2):139-40. PubMed ID: 3551577
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical trial of high doses of Bay I 7433 (Copovithane).
    Ucci G; Riccardi A; Danova M; Faravelli M; Salvini P; Girino M
    Drugs Exp Clin Res; 1986; 12(8):713-5. PubMed ID: 3530678
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacokinetics and tissue disposition of the biological response modifier BAY i 7433 (copovithane) in patients with cancer.
    Rosenblum MG; Hortobagyi GN
    Cancer Chemother Pharmacol; 1986; 18(3):247-51. PubMed ID: 3802380
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Low-dose cyclophosphamide and low-dose interleukin-2 for malignant melanoma.
    Mitchell MS; Kempf RA; Harel W; Shau H; Boswell WD; Lind S; Dean G; Moore J; Bradley EC
    Bull N Y Acad Med; 1989 Jan; 65(1):128-44. PubMed ID: 2532554
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of cyclosporin A on T cell immunity. I. Dose-dependent suppression of different murine T helper cell pathways.
    Fukuzawa M; Shearer GM
    Eur J Immunol; 1989 Jan; 19(1):49-56. PubMed ID: 2522049
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Phase I evaluation of combination therapy with interleukin 2 and gamma-interferon.
    Weiner LM; Padavic-Shaller K; Kitson J; Watts P; Krigel RL; Litwin S
    Cancer Res; 1991 Aug; 51(15):3910-8. PubMed ID: 1906779
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Phase I clinical and pharmacological study of merbarone.
    Dimaggio JJ; Warrell RP; Muindi J; Stevens YW; Lee SJ; Lowenthal DA; Haines I; Walsh TD; Baltzer L; Yaldaei S
    Cancer Res; 1990 Feb; 50(4):1151-5. PubMed ID: 2297763
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Phase I trial of recombinant interleukin-2 and cyclophosphamide: augmentation of cellular immunity and T-cell mitogenic response with long-term administration of rIL-2.
    Kolitz JE; Wong GY; Welte K; Merluzzi VJ; Engert A; Bialas T; Polivka A; Bradley EC; Konrad M; Gnecco C
    J Biol Response Mod; 1988 Oct; 7(5):457-72. PubMed ID: 3263471
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Immunomodulation by recombinant interferon-alpha 2 in a phase I trial in patients with lymphoproliferative malignancies.
    Ozer H; Gavigan M; O'Malley J; Thompson D; Dadey B; Nussbaum-Blumenson A; Snider C; Rudnick S; Ferraresi R; Norred S
    J Biol Response Mod; 1983; 2(6):499-515. PubMed ID: 6607323
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Phase I trial of methotrexate-albumin in a weekly intravenous bolus regimen in cancer patients. Phase I Study Group of the Association for Medical Oncology of the German Cancer Society.
    Hartung G; Stehle G; Sinn H; Wunder A; Schrenk HH; Heeger S; Kränzle M; Edler L; Frei E; Fiebig HH; Heene DL; Maier-Borst W; Queisser W
    Clin Cancer Res; 1999 Apr; 5(4):753-9. PubMed ID: 10213209
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Phase II trial of thymosin fraction 5 and thymosin alpha 1.
    Dillman RO; Beauregard J; Royston I; Zavanelli MI
    J Biol Response Mod; 1987 Jun; 6(3):263-7. PubMed ID: 3598602
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Phase I clinical and pharmacokinetic study of plitidepsin as a 1-hour weekly intravenous infusion in patients with advanced solid tumors.
    Izquierdo MA; Bowman A; García M; Jodrell D; Martinez M; Pardo B; Gómez J; López-Martin JA; Jimeno J; Germá JR; Smyth JF
    Clin Cancer Res; 2008 May; 14(10):3105-12. PubMed ID: 18483378
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Phase I study of N-methylformamide in patients with advanced cancer.
    Ettinger DS; Orr DW; Rice AP; Donehower RC
    Cancer Treat Rep; 1985 May; 69(5):489-93. PubMed ID: 4005871
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Ctla-4 blockade confers lymphocyte resistance to regulatory T-cells in advanced melanoma: surrogate marker of efficacy of tremelimumab?
    Ménard C; Ghiringhelli F; Roux S; Chaput N; Mateus C; Grohmann U; Caillat-Zucman S; Zitvogel L; Robert C
    Clin Cancer Res; 2008 Aug; 14(16):5242-9. PubMed ID: 18698043
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Intralesional treatment of stage III metastatic melanoma patients with L19-IL2 results in sustained clinical and systemic immunologic responses.
    Weide B; Eigentler TK; Pflugfelder A; Zelba H; Martens A; Pawelec G; Giovannoni L; Ruffini PA; Elia G; Neri D; Gutzmer R; Becker JC; Garbe C
    Cancer Immunol Res; 2014 Jul; 2(7):668-78. PubMed ID: 24906352
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A phase I study of recombinant interleukin 2 plus recombinant beta-interferon.
    Krigel RL; Padavic-Shaller KA; Rudolph AR; Litwin S; Konrad M; Bradley EC; Comis RL
    Cancer Res; 1988 Jul; 48(13):3875-81. PubMed ID: 3132324
    [TBL] [Abstract][Full Text] [Related]  

  • 18. WY 18,251 (Tilomisole), an analog of levamisole: tolerability, and immune modulating effects in cancer patients.
    Dillman RO; Ryan KP; Dillman JB; Shawler DL; Maguire R
    Mol Biother; 1992 Mar; 4(1):10-4. PubMed ID: 1385709
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Phase Ib trial of bryostatin 1 in patients with refractory malignancies.
    Grant S; Roberts J; Poplin E; Tombes MB; Kyle B; Welch D; Carr M; Bear HD
    Clin Cancer Res; 1998 Mar; 4(3):611-8. PubMed ID: 9533528
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Phase I clinical investigation of 9,10-anthracenedicarboxaldehyde bis[(4,5-dihydro-1H-imidazol-2-yl)hydrazone] dihydrochloride with correlative in vitro human tumor clonogenic assay.
    Alberts DS; Mackel C; Pocelinko R; Salmon SE
    Cancer Res; 1982 Mar; 42(3):1170-5. PubMed ID: 7037174
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 54.